- $15.91m
- $12.90m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 3.75 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.64 | ||
| Price to Tang. Book | 5.64 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -70.28% | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | 132.52 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
NewcelX AG, formerly NLS Pharmaceutics AG, is a Switzerland-based company primarily engaged in the biotechnology industry. The Company focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The Company offers products like Quilience, which is a clinical-stage pharmaceutical compound. It aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The Company also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The Company is a publicly traded company, listing on the NASDAQ.
Directors
- Ronald Hafner NEC (57)
- Alexander Zwyer CEO (51)
- Subhasis Roy CFO (52)
- Silvia Panigone COO (49)
- Eric Konofal CSO (54)
- Carlos Camozzi OTH (68)
- Myoung-Ok Kwon IND (50)
- Stig Pedersen IND (60)
- Last Annual
- December 31st, 2024
- Last Interim
- June 30th, 2025
- Incorporated
- June 5th, 2015
- Public Since
- January 29th, 2021
- No. of Shareholders
- 28
- No. of Employees
- 1
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 4,558,378
- Address
- The Circle 6, ZUERICH, 8058
- Web
- https://nlspharma.com/
- Phone
- +41 445122150
- Auditors
- Marcum LLP
Upcoming Events for NCEL
Similar to NCEL
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
Acurx Pharmaceuticals
NASDAQ Capital Market
FAQ
As of Today at 12:16 UTC, shares in NewcelX AG are trading at $3.49. This share price information is delayed by 15 minutes.
Shares in NewcelX AG last closed at $3.49 and the price had moved by -89.55% over the past 365 days. In terms of relative price strength the NewcelX AG share price has underperformed the S&P500 Index by -90.89% over the past year.
The overall consensus recommendation for NewcelX AG is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreNewcelX AG does not currently pay a dividend.
NewcelX AG does not currently pay a dividend.
NewcelX AG does not currently pay a dividend.
To buy shares in NewcelX AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $3.49, shares in NewcelX AG had a market capitalisation of $15.91m.
Here are the trading details for NewcelX AG:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: NCEL
Based on an overall assessment of its quality, value and momentum NewcelX AG is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in NewcelX AG is $6.00. That is 71.92% above the last closing price of $3.49.
Analysts covering NewcelX AG currently have a consensus Earnings Per Share (EPS) forecast of -$0.45 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like NewcelX AG. Over the past six months, its share price has underperformed the S&P500 Index by -80.88%.
As of the last closing price of $3.49, shares in NewcelX AG were trading -81.19% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The NewcelX AG PE ratio based on its reported earnings over the past 12 months is 3.75. The shares last closed at $3.49.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
NewcelX AG's management team is headed by:
- Ronald Hafner - NEC
- Alexander Zwyer - CEO
- Subhasis Roy - CFO
- Silvia Panigone - COO
- Eric Konofal - CSO
- Carlos Camozzi - OTH
- Myoung-Ok Kwon - IND
- Stig Pedersen - IND